Literature DB >> 20552561

Synthesis of pathological and nonpathological human exon 1 huntingtin.

David Singer1, Thomas Zauner, Maika Genz, Ralf Hoffmann, Thole Zuchner.   

Abstract

Huntington's disease (HD) is a neurodegenerative disorder that affects approximately 1 in 10 000 individuals. The underlying gene mutation was identified as a CAG-triplet repeat expansion in the gene huntingtin. The CAG sequence codes for glutamine, and in HD, an expansion of the polyglutamine (poly-Q) stretch above 35 glutamine residues results in pathogenicity. It has been demonstrated in various animal models that only the expression of exon 1 huntingtin, a 67-amino acid-long polypeptide plus a variable poly-Q stretch, is sufficient to cause full HD-like pathology. Therefore, a deeper understanding of exon 1 huntingtin, its structure, aggregation mechanism and interaction with other proteins is crucial for a better understanding of the disease. Here, we describe the synthesis of a 109-amino acid-long exon 1 huntingtin peptide including a poly-Q stretch of 42 glutamines. This microwave-assisted solid phase peptide synthesis resulted in milligram amounts of peptide with high purity. We also synthesized a nonpathogenic version of exon 1 huntingtin (90-amino acid long including a poly-Q stretch of 23 glutamine residues) using the same strategy. In circular dichroism spectroscopy, both polypeptides showed weak alpha-helical properties with the longer peptide showing a higher helical degree. These model peptides have great potential for further biomedical analyses, e.g. for large-scale pre-screenings for aggregation inhibitors, further structural analyses as well as protein-protein interaction studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20552561     DOI: 10.1002/psc.1252

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  7 in total

Review 1.  Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence.

Authors:  Ronald Wetzel
Journal:  J Mol Biol       Date:  2012-01-27       Impact factor: 5.469

2.  The 17-residue-long N terminus in huntingtin controls stepwise aggregation in solution and on membranes via different mechanisms.

Authors:  Nitin K Pandey; J Mario Isas; Anoop Rawat; Rachel V Lee; Jennifer Langen; Priyatama Pandey; Ralf Langen
Journal:  J Biol Chem       Date:  2017-12-27       Impact factor: 5.157

3.  An Intein-based Strategy for the Production of Tag-free Huntingtin Exon 1 Proteins Enables New Insights into the Polyglutamine Dependence of Httex1 Aggregation and Fibril Formation.

Authors:  Sophie Vieweg; Annalisa Ansaloni; Zhe-Ming Wang; John B Warner; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2016-03-21       Impact factor: 5.157

4.  Aggregation behavior of chemically synthesized, full-length huntingtin exon1.

Authors:  Bankanidhi Sahoo; David Singer; Ravindra Kodali; Thole Zuchner; Ronald Wetzel
Journal:  Biochemistry       Date:  2014-06-12       Impact factor: 3.162

5.  Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models.

Authors:  Manuel Daldin; Valentina Fodale; Cristina Cariulo; Lucia Azzollini; Margherita Verani; Paola Martufi; Maria Carolina Spiezia; Sean M Deguire; Marta Cherubini; Douglas Macdonald; Andreas Weiss; Alberto Bresciani; Jean-Paul Gerard Vonsattel; Lara Petricca; J Lawrence Marsh; Silvia Gines; Iolanda Santimone; Massimo Marano; Hilal A Lashuel; Ferdinando Squitieri; Andrea Caricasole
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

6.  Beta conformation of polyglutamine track revealed by a crystal structure of Huntingtin N-terminal region with insertion of three histidine residues.

Authors:  Meewhi Kim
Journal:  Prion       Date:  2013-01-31       Impact factor: 3.931

7.  An explorative study towards the chemical synthesis of the immunoglobulin G1 Fc CH3 domain.

Authors:  Luigi Grassi; Cornelia Roschger; Vesna Stanojlović; Chiara Cabrele
Journal:  J Pept Sci       Date:  2018-10-22       Impact factor: 1.905

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.